EP Patent

EP3860597A4 — PI3K INHIBITORS AND THEIR USES

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2022-08-17 · 4y expired

What this patent protects

Patent listed against Piqray.

Drugs covered by this patent

Patent Metadata

Patent number
EP3860597A4
Jurisdiction
EP
Classification
—
Expires
2022-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Memorial Sloan Kettering Cancer Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.